Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats  by Khaper, Neelam & Singal, Pawan K
EXPERIMENTAL STUDY
Modulation of Oxidative Stress
by a Selective Inhibition of
Angiotensin II Type 1 Receptors in MI Rats
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Winnipeg, Canada
OBJECTIVES To examine whether blocking of the renin-angiotensin system (RAS) at the angiotensin II
type 1 (AT1) receptor site is accompanied by changes in the oxidative stress parameters.
BACKGROUND Congestive heart failure in rats after myocardial infarction (MI) has been shown to correlate
with a decrease in antioxidant enzyme activities and an increase in oxidative stress. Inhibition
of the RAS with captopril improves cardiac function and survival in MI rats with a reduction
in oxidative stress.
METHODS Myocardial infarction in rats was produced by ligation of the left coronary artery. At four
weeks after surgery, animals from the sham as well as MI groups were treated with losartan
(2 mg/ml in drinking water daily). At 16 weeks after surgery, the animals were examined for
hemodynamic function and the hearts were analyzed for antioxidant enzyme activities
(superoxide dismutase, glutathione peroxidase and catalase) and oxidative stress (lipid
hydroperoxides, reduced and oxidized glutathione and redox ratio).
RESULTS Congestive heart failure was characterized by dyspnea, depressed hemodynamic function and
presence of lung and liver congestion. This was also associated with a decrease in the
myocardial catalase (225%), glutathione peroxidase (238%) and superoxide dismutase
(242%) activities. An increase in oxidative stress in these hearts was indicated by an increase
in lipid hydroperoxides (167%) and reduction in the redox ratio (275%). Hemodynamic
function was better maintained and there were no indications of dyspnea or lung or liver
congestion in the losartan-treated MI rats. In these animals, myocardial oxidative stress was
markedly reduced and glutathione peroxidase and catalase activities were significantly
improved compared with the untreated MI group.
CONCLUSIONS Blocking of RAS at the AT1 receptor site without the inhibition of angiotensin-converting
enzymes modulates heart failure after MI, and this beneficial effect is associated with a
decrease in oxidative stress. This study suggests a newer role for losartan in the treatment of
heart failure. (J Am Coll Cardiol 2001;37:1461–6) © 2001 by the American College of
Cardiology
In patients surviving a myocardial infarction (MI), the heart
undergoes a remodeling process characterized by hypertro-
phy, which can lead to heart failure. Although hypertrophy
is considered an early response to preserve cardiac function,
numerous studies have suggested that the long-term process
of remodeling has a deleterious effect (1). Although the
mechanisms involved in the transition of the compensatory
phase to the failure stage are poorly understood, chronic
activation of the sympathetic and renin-angiotensin system
(RAS) appears to play a role (2). In this regard, angiotensin-
converting enzyme inhibitors have been shown to improve
cardiac function and prolong life in both experimental and
clinical studies (3,4). Recent data from animal studies (5,6)
as well as patients (7,8) support the role of increased
oxidative stress in the pathogenesis of congestive heart
failure following MI.
Using the rat coronary artery ligation model, our labora-
tory has reported depressed myocardial endogenous antiox-
idant reserve and increased oxidative stress, which were
associated with poor cardiac function (4–6). Inhibition of
the RAS by inhibiting angiotensin-converting enzyme with
captopril in MI rats not only improved hemodynamic
function but also maintained the antioxidant reserve and
decreased oxidative stress (4). Because captopril also pos-
sesses some free-radical scavenging property (9), and inhi-
bition of angiotensin-converting enzyme is also known to
influence bradykinin metabolism (10,11), the exact property
of captopril that offers protection is not clear. Losartan is the
first of the new class of angiotensin II antagonists that
selectively and completely blocks angiotensin II type I
(AT1) receptor (12). Losartan has been reported to reduce
blood pressure and improve cardiac function and survival
(13) without decreasing levels of angiotensin II or other
humoral factors such as bradykinin, vasopressin and pros-
taglandin metabolism (10,12). Thus, a selective inhibition
of AT1 receptor provides an ideal approach for dissecting
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the role of RAS versus other humoral changes during
angiotensin-converting enzyme inhibition in improving the
prognosis in heart failure after MI and associated changes in
oxidative stress.
We used a rat MI model of coronary artery ligation to
explore the effects of RAS inhibition at the AT1 receptor
site by losartan on myocardial antioxidants as well as
oxidative stress changes in relation to the hemodynamic
function in congestive heart failure. Myocardial antioxidant
enzyme (superoxide dismutase, glutathione peroxidase and
catalase) activities and changes in oxidative stress (lipid
hydroperoxide contents, reduced glutathione [GSH] and
oxidized glutathione [GSSG] and GSH/GSSG ratio) were
recorded at 16 weeks post-MI with and without losartan.
The treatment was started at four weeks post-MI and
continued for 12 weeks.
MATERIALS AND METHODS
Animal model and study groups. Male Sprague-Dawley
rats weighing 150 6 10 g were maintained on standard rat
chow and water ad libitum. Myocardial infarction was
produced by occlusion of the left anterior descending
coronary artery and the sham control animals were similarly
treated, except that the suture around the coronary artery
was not tied and the thread was passed only through the
muscle as described before (4). Sham and animals with MI
were divided into four groups as follows: 16-week sham
control (without coronary ligation and without drug); 16-
week post-MI (with coronary ligation but no drug treat-
ment); 16-week sham 1 losartan (no coronary ligation; the
drug was given in drinking water) and 16-week post-MI 1
losartan (coronary-ligated group with the drug treatment).
The treatment with losartan (2 mg/ml in drinking water
daily) was started at four weeks after the surgery and
continued for 12 weeks. Animals were monitored daily for
general behavior, food, water intake and clinical signs of
heart failure. Daily average water consumption in control
and experimental animals was about 30 ml.
Hemodynamic and tissue weight determinations. Rats
were anesthetized with sodium pentobarbital (50 mg/kg
i.p.). A miniature pressure transducer catheter (Millar
Micro-Tip, model PR 249, Houston, Texas) was inserted
into the right carotid artery and then advanced into the left
ventricle. Left ventricular end-diastolic (LVEDP) and left
ventricular peak systolic (LVPSP) pressures were recorded
for an online analysis. After these assessments, the rats were
killed and the heart and other organs removed for further
studies.
In order to obtain the wet/dry weight ratio of the lungs
and liver, these organs were removed and freed from
adhering tissue. In each case, the sample tissue was weighed,
chopped into smaller pieces and placed in the oven (65°C)
until a constant weight was obtained, which was usually
after 24 h.
Biochemical assays for antioxidants and oxidative stress.
For all biochemical assessments, atria, scar and the adhering
tissue from the heart were removed and only the viable
ventricular tissue was used.
Antioxidants. CATALASE. Catalase activity was determined
as previously described (4) and was expressed as mmoles of
H2O2 consumed per minute per milligram protein. Gluta-
thione peroxidase (GSHPx) activity was determined as
previously described (4). Conversion of nicotinamide ade-
nine dinucleotide phosphate reduced (NADPH) to nicotin-
amide adenine dinucleotide phosphate (NADP) was mon-
itored by continuous recording of the change in absorbance
at 340 nm at 1-min intervals for 5 min. Glutathione
peroxidase activity was expressed as nanomoles of reduced
NADPH oxidized to NADP per minute per milligram
protein, with a molar extinction coefficient for NADPH at
340 nm of 6.22 3 106. Superoxide dismutase (SOD)
activity was determined by a previously described method
(4). Superoxide dismutase activity was expressed as units per
milligram protein derived from an SOD standard curve of
pyrogallol oxidation obtained in the presence of commer-
cially available SOD.
Oxidative stress. Oxidative stress was assessed by studying
myocardial GSH and GSSG glutathione and their ratio
(GSH/GSSG) as well as by quantitating lipid hydroperox-
ides.
GLUTATHIONE AND REDOX RATIO. Concentration of total
glutathione (GSSG 1 GSH) was measured in the myocar-
dium by the glutathione reductase/5,59– dithiobis-(2-
nitrobenzoic acid) (DTNB) recycling assay as described
before (5). The rate of DTNB formation was followed at
412 nm and is proportional to the sum of GSH and GSSG
present. Reduced glutathione values were calculated as the
difference between total (GSSG 1 GSH) and GSSG
concentrations.
LIPID HYDROPEROXIDES. This assay was done with a com-
mercial kit that specifically detected lipid hydroperoxides
(LPO-CC assay, Kamiya Biomed Co., Seattle, Washing-
ton) as described earlier (14). This procedure uses a deriv-
ative of methylene blue (10-N-methylcarbonyl-3,7-
dimethylamino-10 H phenothiazine), which is specifically
cleaved by lipid hydroperoxides to yield methylene blue dye,
that can be quantified spectrophotometrically at 675 nm and
compared with standard curve based on the same reaction
with cumene hydroperoxide (15).
Abbreviations and Acronyms
AT1 5 angiotensin II type 1
GSH 5 reduced glutathione
GSHPx 5 glutathione peroxidase
GSSG 5 oxidized glutathione
LVEDP 5 left ventricular end-diastolic pressure
LVPSP 5 left ventricular peak systolic pressure
MI 5 myocardial infarction
RAS 5 renin-angiotensin system
SOD 5 superoxide dismutase
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Proteins and statistical analysis. Proteins were deter-
mined by the method described by Lowry et al. (16). All
results are expressed as mean value 6 SEM. For statistical
analysis of the data, group means were compared by
one-way analysis of variance (ANOVA) followed by the
Bonferroni test. A value of p , 0.05 was considered
significant. Two-way ANOVA test (SPSS System, Win-
dows 10, Chicago, Illinois) was also performed using both
the drug and the surgery as the interaction term.
RESULTS
General characteristics, body weight and mortality.
Sham control and MI rats, both from the untreated and
losartan-treated groups, were monitored periodically. In
terms of general appearance and behavior, nothing unusual
was noted in any of the four groups. The body weight gain
in both the treated and untreated MI groups was slightly
lower than in their respective sham control groups, but the
differences were not significant (p . 0.05). Mortality in the
coronary-artery-ligated animals during or immediately after
the surgery was about 20%. Another ;15% of the animals
died within 24 h following the surgery. The untreated MI
rats appeared lethargic, showing signs of dyspnea in the later
part (12 to 16 weeks) of the study. In contrast, these signs
were not present in the losartan-treated MI rats.
Tissue weights and hemodynamics. Results from the lung
and liver wet/dry weight ratios and the hemodynamic
assessments are summarized in Table 1. The ratio of wet to
dry weight in lung and liver of MI rats was significantly
higher in the 16-week untreated group. Treatment with
losartan ameliorated the increase in these ratios.
Animals were assessed for LVPSP and LVEDP pres-
sures. A significant increase in the LVEDP as well as a
significant decline in the LVPSP were noted in the MI rats
compared with their controls. Losartan treatment attenu-
ated the rise in LVEDP in the MI group. Left ventricular
peak systolic pressure in the losartan-treated MI group was
no longer different from the losartan-treated control group
(Table 1).
Antioxidant enzyme activities. Myocardial catalase,
GSHPx and SOD activities were examined in the viable
myocardium at 16 weeks with and without losartan treat-
ment (Fig. 1A to C). Catalase activity was significantly
decreased (225%) in the 16-week untreated MI group
compared with its respective sham control group (Fig. 1A).
Glutathione peroxidase activity was depressed by about 38%
relative to sham control values (Fig. 1B). A similar trend
was seen with respect to SOD activity (242%) (Fig. 1C).
The catalase activity in the 16 W MI group treated with
losartan showed some improvement; however, this change
was not statistically significant. Losartan treatment in the 16
W C animals resulted in a significant increase in the catalase
Table 1. Lung and Liver Wet/Dry Weight Ratios and Hemodynamic Parameters at 16 Weeks
Post-MI With and Without Losartan Treatment
Parameter
Untreated Losartan-Treated
16 WC 16 MI 16 WC 16 MI
Lung (ratio) 4.5 6 0.16 6.13 6 0.26* 4.6 6 0.13 4.46 6 0.10
Liver (ratio) 3.16 6 0.10 4.01 6 0.2* 3.0 6 0.18 2.97 6 0.04
LVPSP (mm Hg) 124.3 6 1.9 89.58 6 2.9* 117 6 12.66 95.27 6 3.9
LVEDP (mm Hg) 3.38 6 0.4 26.11 6 1.5* 2.83 6 0.4 8.62 6 1*†
Values are mean 6 SE of 6 to 8 animals. *Significantly different (p , 0.05) from the respective control (16 WC) group.
†Significantly different from the respective untreated MI group.
LVEDP 5 left ventricular end-diastolic pressure; LVPSP 5 left ventricular peak systolic pressure; 16 WC 5 16-week sham
control; 16 MI 5 16-week post-myocardial infarction (Post-MI).
Figure 1. Myocardial antioxidant enzyme activities in the 16-week control
(CONT) and myocardial infarction (MI) rats with and without losartan
treatment. Data are mean 6 standard error of the mean, from 5 to 7
animals, with each assay done in duplicate. (A) catalase; (B) glutathione
peroxidase; (C) superoxide dismutase. *Significantly different from the
respective control group; @Significantly different (p , 0.05) from the
respective untreated control and MI groups.
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activity (Fig. 1A). Losartan treatment resulted in significant
improvement in GSHPx activity in the MI group as
compared with the 16 W untreated MI group (Fig. 1B). In
the 16 W MI group treated with losartan, SOD activity
remained unchanged compared with the 16 W MI un-
treated group (Fig. 1C).
Glutathione (reduced and oxidized). Myocardial GSH
and GSSG contents were examined in the 16-week sham
and MI groups with and without losartan treatment (Table
2). Myocardial GSH content at 16 weeks in the untreated
MI group was significantly (p , 0.001) decreased by about
40% compared with its respective sham control group.
Oxidized glutathione content was increased by about 114%
in the 16 W MI group (Table 2). The GSH content in the
losartan-treated C as well as MI groups was significantly
improved. Oxidized glutathione content in the losartan-
treated MI group was decreased and the values no longer
were different from the respective sham control group.
Redox ratio was also assessed in the 16 W sham control and
MI group with and without losartan treatment; the results
are presented in Figure 2A. The redox ratio was significantly
depressed in the 16 W MI group compared with its
respective sham control group. This ratio was significantly
improved in both the control and MI groups treated with
losartan (Fig. 2A).
Lipid hydroperoxides. In order to assess the degree of lipid
peroxidation during heart failure, lipid hydroperoxide for-
mation was determined (Fig. 2B). Lipid hydroperoxide
content was significantly higher (p , 0.05) in the 16 W MI
group compared with its respective sham control group.
This increase in the lipid hydroperoxide content was signif-
icantly attenuated (p , 0.05) in the 16 W MI group treated
with losartan (Fig. 2B).
Analysis of the data using two-way ANOVA further
confirmed that losartan had an effect on all parameters in
the surgery (MI) group except for LVPSP, SOD and
catalase.
DISCUSSION
Heart failure and remodeling. Animals in the 16-week
untreated MI group exhibited congestive heart failure as
indicated by labored breathing, an increase in LVEDP,
decrease in LVPSP and the presence of lung and liver
congestion. Losartan treatment modulated the increase in
LVEDP. Furthermore, there was no lung or liver conges-
tion in the losartan group. This study also demonstrates for
the first time that losartan, in addition to reducing cardiac
remodeling and improving survival as reported by other
investigators (13,17,18), also reduces oxidative stress and
maintains myocardial endogenous antioxidants in the MI
model of heart failure.
Renin-angiotensin system and heart failure: angiotensin-
converting enzyme inhibition and AT1 blockade. Angio-
tensin II (AII) exerts its physiological effects by binding
either to AT1 or AT2 receptors located on the plasma
membrane of various tissues including the heart (12).
Angiotensin-converting enzyme inhibitors have a proven
role in the management of patients (3) and animals with
heart failure (4). However because of the limited efficacy of
angiotensin-converting enzyme inhibitors in blocking the
Table 2. Myocardial Reduced (GSH) and Oxidized (GSSG) Glutathione Levels in Sham






C Post-MI C Post-MI
16 weeks 71.53 6 1.32 42.68 6 1.3* 8.63 6 0.51 18.51 6 1.2*
16 weeks 1 losartan 88.66 6 4.1† 77.73 6 7.1† 7.25 6 0.4 8.12 6 1.32
Values are mean 6 SE of 5 to 7 hearts. *Significantly different (p , 0.001) from the respective control (C) group. †Significantly
different from the respective untreated control or myocardial infarction (MI) group.
GSH 5 reduced glutathione; GSSG 5 oxidized glutathione.
Figure 2. Redox ratio (A) and lipid hydroperoxide content (B) in the
16-week control and MI rats with and without losartan treatment. Data are
mean 6 SEM from 8 to 10 animals with each assay done in duplicate.
*Significantly different (p , 0.05) from the respective control group;
@Significantly different from the respective untreated control or myocardial
infarction group.
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RAS and their additional effects on bradykinin and prosta-
glandin metabolism (10,19,20), AII receptor blockers are
considered an attractive alternative to angiotensin-
converting enzyme inhibitors.
Losartan selectively and specifically inhibits AT1-
mediated actions of AII irrespective of the pathway by
which AII is formed (12), and it is considered to be about
10,000 times more selective for AT1 receptors (21). The
effects of losartan on the RAS have been examined before
(17). Furthermore, losartan is known to have no inhibitory
effects on vasopressin, bradykinin or prostaglandin metab-
olism (10). Numerous studies have demonstrated reversal
of left ventricular hypertrophy, reduced fibrosis, improve-
ment in coronary flow and cardiac function following
losartan treatment (18,22). It is known that captopril also
improves the prognosis (3) as well as myocardial SOD,
GSHPx and catalase activities after MI (4). Losartan, in the
present study, improved GSHPx activity. Because both
angiotensin-converting enzyme inhibition with captopril (4)
and AT1 blockade with losartan in this study modulated
heart failure, we suggest that the beneficial effects of
angiotensin-converting enzyme inhibition are indeed due to
the blockade of AII effects rather than any other humoral
changes seen with angiotensin-converting enzyme inhibi-
tion.
Oxidative stress and heart failure. Myocardial antioxi-
dants are dynamic in nature and have been reported to
change in various physiological and pathological conditions,
including hypertrophy (23), exercise (24) and adriamycin-
induced cardiomyopathy (25). It is also known that different
enzymatic and nonenzymatic antioxidants respond uniquely
in a variety of oxidative stress conditions. For example,
hypoxia resulted in a reduction in MnSOD and GSHPx
activities with no change in CAT activity (26). After
reoxygenation, MnSOD activity was recovered, but not
GSHPx activity (26). In the pressure-overload-induced
model of heart failure, only SOD activity was significantly
less in the failure group, with no changes in the GSHPx and
CAT activities (27). More recently, we also reported unique
regional differences in nonenzymatic antioxidants in hearts
subjected to ischemia reperfusion (14). The exact stimulus
for the altered activity of these enzymes is not known;
however, increased free radical formation and/or lipid per-
oxidation during stress conditions may act as a signal (28).
Thus, it is clear that different antioxidants respond to
various stimuli in a specific manner and may adapt accord-
ing to the requirement or condition imposed. In the present
study, SOD, GSHPx and catalase activities were signifi-
cantly decreased in the 16-week MI group. Glutathione
peroxidase, which is one of the most important antioxidants
in the heart, was significantly improved in MI rats by
losartan. Catalase activity was also increased in the losartan-
treated control animals.
The severe heart failure stage in this study was accompa-
nied by depressed levels of GSH and increased levels of
GSSG. A significant decrease in the redox ratio (GSH/
GSSG) indicated an increase in the oxidative stress (29) in
the viable myocardium of the MI rats as compared with the
control. In addition to the redox ratio, the lipid hydroper-
oxide content was also significantly higher in the MI rats,
further supporting the observation of an increase in oxida-
tive stress in these hearts. The increased concentration of
lipid hydroperoxides in cellular membranes is indicative of
actual damage mediated by oxygen radicals (15). Changes in
the GSH levels as well as lipid hydroperoxides in the
losartan-treated groups could not be attributed to any direct
interference by the drug itself. This is due to the fact that
the half-life of losartan is about 2 h (30), whereas the assays
for glutathione and lipid hydroperoxides in this study were
done at 48 h after the last injection of the drug. Thus, there
will hardly be any residual activity of losartan, and the
changes seen in these parameters are most likely the result of
in vivo effects of the drug.
Oxidative stress was significantly reduced by treatment
with losartan, as indicated by an increase in the redox ratio
and decreased lipid hydroperoxide content in the MI group.
We have previously reported that heart failure after MI in
rats correlated with depressed antioxidant reserve and in-
creased oxidative stress (5). Diet supplemented with biolog-
ical antioxidant vitamin E improved endogenous levels of
vitamin E and cardiac function, suggesting a cause-and-
effect relationship between increased oxidative stress and
cardiac dysfunction (6).
A recent study on atherosclerosis Apo-E deficient mice
documented that treatment with losartan reduced low den-
sity lipoprotein peroxidation in the atherosclerotic lesion
area (31). Losartan treatment in rabbits normalized vascular
superoxide anion (O2
2) production in a dose-dependent
manner and prevented tolerance to nitroglycerine (32).
Another study showed AII increases in hypertensive rats
that were associated with increased vascular smooth-muscle
cell O2
2 production via NADH/NADPH oxidase activa-
tion and losartan treatment in these rats’ normalized O2
2
production (33). It has also been reported that in oxidative
stress conditions, there is an increase in superoxide anion,
which reacts with nitric oxide (a potent vasodilator) to
produce peroxynitrite that causes vasoconstriction (34).
Thus, losartan appears to modulate free radical production,
increase antioxidants and reduce oxidative stress.
Arrhythmias and sudden death. Catecholamine-induced
arrhythmias and sudden death due to excessive cat-
echolamines are suggested to be mediated by increased
oxidative stress (35). The reduced incidence of sudden death
due to losartan, reported in the Evaluation of Losartan in
the Elderly (ELITE 1) Study (13), may partly be explained
by a decrease in production of catecholamines due to AT1
blockade with this drug (36), as well as a reduction in
oxidative stress because of an inhibition of RAS seen both in
this and in earlier (4) studies.
Conclusions. This study documents for the first time that
inhibition of the AT1 receptor with losartan, not only
improves cardiac function but also causes an improvement
1465JACC Vol. 37, No. 5, 2001 Khaper and Singal
April 2001:1461–6 Losartan and Oxidative Stress Changes
in the myocardial antioxidant reserve and decreased oxida-
tive stress in MI rats, suggesting a new role for losartan in
the treatment of heart failure. The precise mechanism(s) for
decrease in oxidative stress and improvement in antioxidant
reserve after losartan treatment is unclear at this time. The
study also emphasizes that modulation of the RAS, either
by angiotensin-converting enzyme inhibition or by AT1
receptor blockade, is beneficial and may not involve other
humoral changes seen after angiotensin-converting enzyme
inhibition.
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